HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

LY 165163 (PAPP)

structure given in first source; a serotonin agonist
Also Known As:
PAPP; 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine; LY 165163, hydrochloride; LY-165163; p-NH2-PE-TFMPP
Networked: 32 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Eason, Charles T: 2 articles (12/2013 - 03/2010)
2. Hernández, Jairo: 2 articles (06/2011 - 06/2010)
3. Martín-Vasallo, Pablo: 2 articles (06/2011 - 06/2010)
4. González-Fernández, Rebeca: 2 articles (06/2011 - 06/2010)
5. Palumbo, Angela: 2 articles (06/2011 - 06/2010)
6. Jellinger, Kurt A: 2 articles (06/2010 - 09/2003)
7. Bahar, Bojlul: 1 article (08/2015)
8. Brayden, David J: 1 article (08/2015)
9. Maher, Sam: 1 article (08/2015)
10. Walsh, Edwin: 1 article (08/2015)

Related Diseases

1. Psoriasis (Pustulosis Palmaris et Plantaris)
10/01/2012 - "Papp et al. and Leonardi et al. concluded that brodalumab and ixekizumab, respectively, significantly improved plaque psoriasis in 12-week, phase II studies. "
10/01/2012 - "In these phase II, multicentre, randomized, double-blind, placebo-controlled, dose-ranging studies, 198 patients with severe chronic plaque-type psoriasis [Psoriasis Area and Severity Index (PASI) ≥ 12, body surface area (BSA) ≥ 10] were enrolled in Papp et al. between December 2009 and April 2010 and 142 patients in Leonardi et al. between April 2010 and March 2011. "
10/01/2012 - "STUDY EXPOSURE: In Papp et al., patients with chronic plaque-type psoriasis were randomly assigned to receive placebo or brodalumab at a dose of 70, 140 or 210 mg, administered subcutaneously on day 1 and at weeks 1, 2, 4, 6, 8 and 10, or at a dose of 280 mg administered subcutaneously on day 1 and at weeks 4 and 8. In Leonardi et al., patients were randomly assigned to receive subcutaneous injections of placebo or 10, 25, 75 or 150 mg of ixekizumab at 0, 2, 4, 8, 12 and 16 weeks, followed by a 4-week follow-up period. "
10/01/2012 - "Additionally in Papp et al. the BSA and Medical Outcomes Study 36-item short-form health survey, and in Leonardi et al. the joint pain visual analogue scale (VAS), itch severity VAS, Nail Psoriasis Severity Index (NAPSI) and the Psoriasis Scalp Severity Index (PSSI) were also measured. "
10/01/2012 - "Papp et al. (N Engl J Med 2012; 366: 1181-9) and Leonardi et al. (N Engl J Med 2012; 366: 1190-9) respectively assessed the efficacy and safety of brodalumab (AMG 827), a human monoclonal antibody directed against interleukin (IL)-17RA, the receptor of IL-17A and ixekizumab (LY2439821), a humanized anti-IL-17 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis. "
2. Poisoning
3. Renal Colic
4. Arthralgia (Joint Pain)
5. Ectopic Pregnancy

Related Drugs and Biologics

1. Messenger RNA (mRNA)
2. Stem Cell Factor
3. FSH Receptors (FSH Receptor)
4. 4-aminopropiophenone
5. Pregnancy-Associated Plasma Protein-A (PAPP-A)
6. piperazine
7. Serotonin 5-HT1 Receptor Antagonists
8. Serotonin 5-HT1 Receptor Agonists
9. Caspase 9
10. Caspase 3 (Caspase-3)

Related Therapies and Procedures

1. Subcutaneous Injections
2. Heterologous Transplantation (Xenotransplantation)